Deuterated Domperidone Composition for Slower Metabolism and Lower Dosing

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for gastroparesis, such as domperidone, face challenges with significant side effects, limited efficacy due to rapid metabolism, and require frequent dosing, which can lead to cardiac issues like QT prolongation.

Innovation Solution

Administering deuterated forms of domperidone, specifically domperidone-d4, domperidone-d6, or their pharmaceutically acceptable salts, to slow down metabolism and increase drug retention, allowing for lower doses and reduced side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If domperidone is administered to treat gastroparesis, then gastrokinetic and antiemetic effects are achieved, but frequent dosing is required due to rapid metabolism

Engineering Contradiction:
Improvetherapeutic efficacyVSAvoiddrug retention time
Core Design Contradiction:
ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent applies parameter changes by substituting hydrogen atoms with deuterium atoms in the domperidone molecule. This isotopic substitution alters the metabolic parameters of the drug, specifically slowing down CYP3A4-mediated metabolism through the kinetic isotope effect. The deuterated domperidone maintains the same therapeutic effects as conventional domperidone but with extended half-life and reduced clearance, thereby resolving the contradiction between maintaining therapeutic efficacy and extending duration of action.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If domperidone dosage is increased to maintain therapeutic levels, then efficacy is improved, but cardiac side effects like QT prolongation increase

Engineering Contradiction:
Improvetherapeutic efficacyVSAvoidcardiac side effects
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent utilizes parameter changes through deuterium substitution to alter the pharmacokinetic profile of domperidone. The deuterated analog exhibits slower metabolism and reduced clearance, allowing maintenance of therapeutic plasma concentrations at lower doses. This resolves the contradiction by achieving the same therapeutic efficacy with reduced dosing, thereby minimizing exposure-related cardiac side effects such as QT interval prolongation.

Inventive Principle:
Principle #35Parameter changes

3Reliability

If domperidone is administered frequently to overcome rapid metabolism, then therapeutic levels are maintained, but side effects and patient compliance issues increase

Engineering Contradiction:
Improvetherapeutic level maintenanceVSAvoiddosing frequency
Core Design Contradiction:
ReliabilityVSEase of operation

Solution Approach 1:

The patent applies parameter changes by introducing deuterium atoms at specific positions in the domperidone molecule, which slows metabolic degradation through the kinetic isotope effect. This extends the elimination half-life from approximately 7.5 hours for conventional domperidone to longer durations for deuterated versions, enabling less frequent dosing while maintaining therapeutic levels, thus improving ease of operation and patient compliance.

Inventive Principle:
Principle #35Parameter changes

4Ease of manufacture

If conventional domperidone is used, then treatment is accessible, but metabolism is rapid leading to reduced efficacy over time

Engineering Contradiction:
Improvedrug accessibilityVSAvoidmetabolic stability
Core Design Contradiction:
Ease of manufactureVSReliability

Solution Approach 1:

The patent employs parameter changes through isotopic substitution with deuterium to enhance metabolic stability. The deuterated domperidone maintains the same molecular structure and pharmacological activity as conventional domperidone, ensuring continued accessibility, while the C-D bonds resist metabolic cleavage more effectively than C-H bonds, thereby improving reliability and metabolic stability without compromising ease of manufacture.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Deuterated domperidone provides enhanced efficacy with fewer side effects and improved pharmacokinetics, enabling lower dosing frequencies and maintaining therapeutic levels.

Implementation Method 1

deuterated forms of domperidone, specifically domperidone-d4, domperidone-d6, or their pharmaceutically acceptable salts, to slow down metabolism and increase drug retention

Methodology Applied
Scientific EffectKinetic isotope effect:

Data Source

PatentUS12478612B2Deuterated domperidone compositions, methods, and preparation
Publication Date: 2025.11.25 CINDOME PHARMA INC
  • US12478612B2 patent drawing
  • US12478612B2 patent drawing
  • US12478612B2 patent drawing

AI summary

Deuterated domperidone compositions, methods of synthesis, methods of use, and dosing formulations providing beneficial safety and other effects.